Ustekinumab therapy for Netherton syndrome

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Netherton syndrome (NS) is a rare genetic disorder of cornification.
• NS results from SPINK5 mutations affecting serine protease inhibitor LEKTI.
• Th17 pathway skewing and IL-23 upregulation are implicated in NS pathogenesis.

Purpose of the Study:

• To evaluate the therapeutic efficacy of ustekinumab in patients with Netherton syndrome.
• To assess ustekinumab's impact on disease severity, quality of life, and itch.
• To analyze changes in inflammatory markers via histopathology.

Main Methods:

• A case series involving three NS patients treated with six doses of ustekinumab over 13 months.
• Disease assessment using Ichthyosis Area and Severity Index (IASI), Dermatology Life Quality Index (DLQI), visual analogue scale (VAS) for itch, and peak-pruritus numeric rating scale (PP-NRS).
• Histopathology with CD3, CD4, CD8, and IL-17 immunostaining at baseline and 4 weeks post-treatment.

Main Results:

• Two patients showed a 28% reduction in IASI scores by week 16, sustained to week 56.
• No consistent improvements were observed in DLQI, VAS, or PP-NRS scores.
• Slight reductions in inflammatory infiltrate and acanthosis were noted, but no significant changes in immunostaining for inflammatory markers.

Conclusions:

• This case series did not demonstrate a significant therapeutic effect of ustekinumab in Netherton syndrome.
• Targeting IL-23/Th17 pathways with ustekinumab may not be a consistently effective treatment for NS.
• Further research is needed to explore alternative therapeutic strategies for NS.